ClinicalTrials.gg
CompletedNCT06181370Updated Jun 23, 2026

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

A Phase 1 interventional study of AGMB-447 and placebo in IPF, sponsored by Agomab Spain S.L.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Agomab Spain S.L. (part of Agomab Therapeutics NV) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C).

Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of AGMB-447 administered via nebulizer in Part A, B and C, respectively.

02

Conditions studied

  • IPF
03

In context

Lead sponsor

Agomab Spain S.L. is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted after Agomab Spain S.L. became part of Agomab Therapeutics NV.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria for Healthy Participants (Parts A and B):

  • Male and female participants aged between 18-55 years inclusive, at the time of .
  • Participants must have ≥80% predicted at screening and prior to randomization on Day -1 or Day 1 of treatment period 1 (using Global Lung Index, GLI 2012, predicted values).
  • Participant must have a body weight of at least 50.0 kg and ≥ 18 and ≤ 32 kg/m2 at screening.
  • Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead , spirometry and clinical laboratory assessments at the time of screening, as judged by the Investigator.

Inclusion criteria

Inclusion Criteria for IPF Participants (Part C)

  • Male and female participants aged >40 years inclusive, at the time of informed consent.
  • Participants must have a confirmed diagnosis of IPF (IPF based on 2022 ATS/ERS/JRS/ALAT Guidelines) as confirmed by the Investigator based on chest High Resolution Computed Tomography Scan taken within 5 years of screening and, only if available, surgical lung )
  • Participants must be either:
  • Receiving a stable, well tolerated dose of Nintedanib for 3 months prior to screening for the treatment of IPF
  • OR
  • Receiving no current antifibrotic medication for the treatment of IPF. This includes those who have never received treatment and those who have stopped medication due to intolerance for any reason, except non-responsiveness, for at least 6 weeks prior to screening.
  • Participants must have FVC ≥40% of predicted (using Global Lung Index, GLI 2012, predicted values) at screening.
  • Participants must have DLCO (corrected for ) ≥ 25% of predicted (using Global Lung Index, GLI 2017, predicted values) at screening.
  • Participants must have FEV1 ≥30% predicted at screening and prior to randomization on Day -1 or Day 1 (using Global Lung Index, GLI 2012, predicted values).

Exclusion criteria for Healthy Participants (Parts A and B)

  • History or presence of any acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical study or expose the participant to undue risk as judged by the Investigator.
  • After a minimum of 10 minutes supine rest at the time of screening or prior to randomization on Day -1 or Day 1 of treatment period 1:

    • Systolic blood pressure \<90 or >150 mmHg, or
    • Diastolic blood pressure \<50 or >95 mmHg, or
    • Pulse \<40 or >90 bpm
  • Any clinically significant abnormalities in resting ECG at the time of screening or prior to randomization on Day -1 or Day 1 of treatment period 1 including prolonged (>450 ms for males; >470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator.
  • Clinically significant abnormalities in renal function at screening including any of the following:

    • Serum creatinine >2 x
    • \<80 mL/min
  • Clinically significant abnormalities in liver function at screening including any of the following:

    • >1.5 x ULN
    • Aminotransferases >2 x ULN
    • ALP >1.5 x ULN

Exclusion criteria

Exclusion Criteria for IPF Participants (Part C)

  • History or presence of any acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical study or expose the participant to undue risk as judged by the Investigator.
  • History or presence of any clinically significant pulmonary abnormalities, with the exception of IPF, in the opinion of the Investigator.
  • Relevant airways obstruction (pre-bronchodilator / FVC \< 0.7) at screening.
  • Any clinically significant abnormalities in resting at the time of screening or prior to randomization on Day -1 or Day 1 including prolonged (>450 ms for males; >470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator.
  • Clinically significant abnormalities in liver function at screening including any of the following:

    • >1.5 x
    • Aminotransferases >2 x ULN
    • ALP >1.5 x ULN
  • Acute IPF exacerbation within 3 months prior to screening and/or during the screening period prior to dose on Day 1 as determined by the Investigator.
  • Any signs of respiratory tract infection within 4 weeks of screening or prior to dosing on Day 1 that is deemed clinically significant in the opinion of the Investigator.
  • within the past 5 years of screening with the exception of in situ removal of basal cell carcinoma or resected benign colonic polyps.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    AGMB-447

    Participants will receive a single dose of AGMB-447 (part A), multiple doses of AGMB-447 over 7 days (part B) or multiple doses of AGMB-447 over 14 days (part C)

    Drug: AGMB-447

  • Placebo comparator
    placebo

    Participants will receive a single dose of placebo (part A), multiple doses of placebo over 7 days (part B) or multiple doses of placebo over 14 days (part C)

    Other: placebo

Interventions

  • DrugAGMB-447

    AGMB-447 inhaled drug

  • Otherplacebo

    placebo inhaled drug

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    To evaluate the safety and tolerability of AGMB-447 in terms of AE at every visit

    Time frame: From Screening Through Study Completion, up to 8 Weeks

  2. Number of participants with abnormal clinical laboratory values

    To evaluate the safety and tolerability of AGMB-129 in terms of abnormal laboratory parameters at every visit

    Time frame: From Screening Through Study Completion, up to 8 Weeks

  3. Number of participants with abnormal ECG parameters

    To evaluate the safety and tolerability of AGMB-447 in terms of abnormal ECGs at every visit

    Time frame: From Screening Through Study Completion, up to 8 Weeks

  4. Number of participants with abnormal vital signs

    To evaluate the safety and tolerability of AGMB-447 in terms of vital signs at every visit

    Time frame: From Screening Through Study Completion, up to 8 Weeks

  5. Number of participants with abnormal physical exams

    To evaluate the safety and tolerability of AGMB-447 in terms of physical exams at every visit

    Time frame: From Screening Through Study Completion, up to 8 Weeks

  6. Number of participants with abnormal spirometry parameters

    To evaluate the safety and tolerability of AGMB-447 in terms of spirometry at every visit

    Time frame: From Screening Through Study Completion, up to 8 Weeks

Secondary outcomes

  1. Plasma levels of AGMB-447

    To characterize the pharmacokinetics (PK) of AGMB-447 by measuring the amount in plasma

    Time frame: From Screening Through Study Completion, up to 8 Weeks

  2. Plasma levels of the major metabolite

    To characterize the pharmacokinetics (PK) of the major metabolite by measuring the amount in plasma

    Time frame: From Screening Through Study Completion, up to 8 Weeks

07

Study locations

1 site
  • Medicines Evaluation Unit Ltd. an IQVIA business
    Manchester, M23 9QZ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Apr 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Dec 26, 2023
StartActual
Dec 1, 2023
Primary completionActual
Apr 29, 2026
CompletionActual
Apr 29, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06181370
Lead sponsor
Agomab Spain S.L.
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Dec 1, 2023
Primary completion
Apr 29, 2026
Completion
Apr 29, 2026
Last update
Jun 23, 2026

Study contacts

Philippe Wiesel, MD
study director · Agomab Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion